SEC Comment Letter for Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281) (PLX) — Dec 30, 2010
Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)
Date: Dec. 30, 2010 · CIK: 0001006281 · Accession: 0000000000-10-078173
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-33357
Letter
Via Facsimile and U.S. Mail December 30, 2010 David Aviezer, Ph.D. President and Chief Executive Officer Protalix Biotherapeutics , Inc. 2 Snunit St., Science Park POB 455, Carmiel 20100, Israel
Re: Protalix Biotherapeutics, Inc. Form 10 -K for the Fiscal Year Ended December 31 , 2009 Filed February 26 , 2010 File No. 001-33357
Dear Dr. Aviezer :
We have completed our review of your filings and do not have any further comments at this time.
Sincerely,
Jeffrey Riedler
Assistant Director
Show Raw Text
Via Facsimile and U.S. Mail December 30, 2010 David Aviezer, Ph.D. President and Chief Executive Officer Protalix Biotherapeutics , Inc. 2 Snunit St., Science Park POB 455, Carmiel 20100, Israel Re: Protalix Biotherapeutics, Inc. Form 10 -K for the Fiscal Year Ended December 31 , 2009 Filed February 26 , 2010 File No. 001-33357 Dear Dr. Aviezer : We have completed our review of your filings and do not have any further comments at this time. Sincerely, Jeffrey Riedler Assistant Director cc: James R. Tanenbaum , Esq. Joseph Magnas, Esq. Neeraj Kumar, Esq. Morrison & Foerster LLP 1290 Avenue of the Americas New York, NY 10104 -0050